SOLIGENIX 2 RSS Feed | Nachrichten - www.finanzen.netwww.finanzen.net bietet Finanznachrichten zum weltweiten BörsengeschehenFinanzenhttps://www.finanzen.netde-definanzen.net GmbHThu, 21 May 2026 18:53:21 +0200https://images.finanzen.net/images/finanzen_net_neu.gifSOLIGENIX 2 RSS Feed | Nachrichten - www.finanzen.nethttps://www.finanzen.netPositive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)Thu, 18 Dec 2025 13:30:00 +0100https://www.finanzen.net/nachricht/aktien/positive-clinical-results-from-phase-2-trial-of-sgx945-for-the-treatment-of-behçet-s-disease-published-in-rheumatology-oxford-15367979
  • Study results support advancing SGX945 in this difficult-to-treat orphan disease
  • Results suggest potential durability of response for maintenance therapy

]]>https://www.finanzen.net/nachricht/aktien/positive-clinical-results-from-phase-2-trial-of-sgx945-for-the-treatment-of-behçet-s-disease-published-in-rheumatology-oxford-15367979Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate PsoriasisWed, 17 Dec 2025 13:30:00 +0100https://www.finanzen.net/nachricht/aktien/soligenix-announces-top-line-results-of-the-phase-2a-study-of-sgx302-synthetic-hypericin-in-patients-with-mild-to-moderate-psoriasis-15364814

Optimized Gel Formulation Demonstrates Clinical Success in Third Cohort of Patients

PRINCETON, ...

]]>https://www.finanzen.net/nachricht/aktien/soligenix-announces-top-line-results-of-the-phase-2a-study-of-sgx302-synthetic-hypericin-in-patients-with-mild-to-moderate-psoriasis-15364814